Universities
are a primary source of discovery and are playing an ever increasing role as
economic engines through technology transfer and university spin-outs. Growing
a culture of ‘open’ innovation by tapping into resources from the corporate
community will further develop entrepreneurial ideas and promote economic
innovation.
Research
Commercialisation: From Ideas to IPO [17-18 October 2013, Brussels, Belgium – www.idea2ipo-conference.com]
is a new cross-discipline partnering event and will provide a platform for
promoting university-industry-investor collaboration, technology transfer and
start-ups to further research commercialisation and regional economic growth.
Expert
speakers from the US and Europe will provide topical insight and first hand
case study experience on the challenges, risks and opportunities associated
with entrepreneurial projects that commercialise university-owned intellectual
property.
Claude
Kaplan, Managing Director at IP Pragmatics and one of the conference speakers,
notes: “There have been massive advances in facilitating commercial
interactions between universities and industry; with new models, better
understanding of the different cultures and a convergence of inter-dependency.
However significant barriers still exist which are greatly limiting the
commercialisation of research and resulting in a very poor rate of research
commercialisation. Making the next step-change will require a fundamental shift
in the way we fund science, the ways companies interact with universities and
the culture of researchers, companies and university research managers."
This
conference will address these issues focussing on best practices in technology
transfer and bringing research to the market, promoting academic-industry
collaboration and providing expert insight into intellectual property and
Investment strategies. A key feature will be promoting networking to facilitate
future partnerships.
During
the two-day programme academic representatives from knowledge transfer
departments in leading universities and company executives from start-up
companies will share experiences in
founding and managing academic spin-off companies. Delegates will learn how
university venturing is increasingly important to a region's innovation success
and to the academic institutions' own chances of remaining in the top tier.
From
an industry perspective: Andreas Jenne CEO and Roman Thomas Chief Scientific
Officer of BLACKFIELD AG, Germany are among those who will provide case study
insight into the challenges of launching a company and the opportunities for
funding. Malcolm Skingle, Director of Academic Liaison, GlaxoSmithKline will cover
specific GSK models designed to encourage closer relationships with academia in
order to develop new medicines.
For
further information on the speaker line-up and details of special delegates
rates please visit: www.idea2ipo-conference.com
No comments:
Post a Comment